CAZZANIGA MARINA ELENA

Cristoferi, L., D'Amato, D., Maino, C., Bernasconi, D., Dinelli, M., Malandrin, S., et al. (2026). Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial. BMJ OPEN, 16(1) [10.1136/bmjopen-2025-106630]. Detail

Ardakani, K., Passarella, G., Lania, A., Clementi, T., Fanti, A., Pepe, F., et al. (2026). Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review. CURRENT ONCOLOGY, 33(1) [10.3390/curroncol33010028]. Detail

Cazzaniga, M., Cogliati, V., Rossi, E., Paris, I., Borella, F., Moretti, G., et al. (2026). Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study. ESMO REAL WORLD DATA AND DIGITAL ONCOLOGY, 11(March 2026) [10.1016/j.esmorw.2025.100665]. Detail

Cazzaniga, M., Costa, L., Freyer, G., Gligorov, J., Lindman, H., Wysocki, P., et al. (2025). Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review. ONCOLOGY AND THERAPY [10.1007/s40487-025-00398-4]. Detail

Liu, J., Mo, H., Li, Q., Cazzaniga, M., Ma, F. (2025). Metronomic Chemotherapy in Breast Cancer: Unleashing the Potential of Combination Regimens. CANCER INNOVATION, 4(6) [10.1002/cai2.70035]. Detail